These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15172014)

  • 21. Genomics and the search for novel biomarkers in toxicology.
    Tugwood JD; Hollins LE; Cockerill MJ
    Biomarkers; 2003; 8(2):79-92. PubMed ID: 12775494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. State-of-the-art genomics approaches in toxicology.
    Van Hummelen P; Sasaki J
    Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat oral dose toxicity studies of melamine in rats and monkeys.
    Early RJ; Yu H; Mu XP; Xu H; Guo L; Kong Q; Zhou J; He B; Yang X; Huang H; Hu E; Jiang Y
    Arch Toxicol; 2013 Mar; 87(3):517-27. PubMed ID: 23052191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent successes in the identification, development, and qualification of translational biomarkers: the next generation of kidney injury biomarkers.
    Ennulat D; Adler S
    Toxicol Pathol; 2015 Jan; 43(1):62-9. PubMed ID: 25492424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro.
    Rached E; Hoffmann D; Blumbach K; Weber K; Dekant W; Mally A
    Toxicol Sci; 2008 Jun; 103(2):371-81. PubMed ID: 18308701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue expression and correlation of a panel of urinary biomarkers following cisplatin-induced kidney injury.
    Wadey RM; Pinches MG; Jones HB; Riccardi D; Price SA
    Toxicol Pathol; 2014; 42(3):591-602. PubMed ID: 23823703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicogenomics in biomarker discovery.
    Decristofaro MF; Daniels KK
    Methods Mol Biol; 2008; 460():185-94. PubMed ID: 18449488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preface.
    Ferrer-Dufol A; Vericat JA
    Toxicol Lett; 2009 Apr; 186(1):1. PubMed ID: 19373986
    [No Abstract]   [Full Text] [Related]  

  • 30. Transcriptional profiling to identify biomarkers of disease and drug response.
    Mendrick DL
    Pharmacogenomics; 2011 Feb; 12(2):235-49. PubMed ID: 21332316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity.
    Beger RD; Sun J; Schnackenberg LK
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):154-66. PubMed ID: 19932708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury.
    Waring WS; Moonie A
    Clin Toxicol (Phila); 2011 Oct; 49(8):720-8. PubMed ID: 21970770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolomics for early detection of drug-induced kidney injury: review of the current status.
    Boudonck KJ; Rose DJ; Karoly ED; Lee DP; Lawton KA; Lapinskas PJ
    Bioanalysis; 2009 Dec; 1(9):1645-63. PubMed ID: 21083109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New effect biomarkers].
    De Palma G; Corradi M; Mutti A; Baccarelli A; Pesatori A; Bertazzi PA
    G Ital Med Lav Ergon; 2004; 26(4):302-10. PubMed ID: 15584437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic.
    Russell C; Rahman A; Mohammed AR
    Ther Deliv; 2013 Mar; 4(3):395-413. PubMed ID: 23442083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular biomarkers in drug development.
    Lewin DA; Weiner MP
    Drug Discov Today; 2004 Nov; 9(22):976-83. PubMed ID: 15539141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicogenomic analysis methods for predictive toxicology.
    Maggioli J; Hoover A; Weng L
    J Pharmacol Toxicol Methods; 2006; 53(1):31-7. PubMed ID: 16236530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic and genetic biomarkers of toxicity.
    Mendrick DL
    Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspective on the use of genomic biomarkers in the clinical setting.
    Agúndez JA; Sinclair E
    Pharmacogenomics; 2014 Mar; 15(4):419-22. PubMed ID: 24624909
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical use of biomarkers for toxicant-induced acute kidney injury.
    Pianta TJ; Buckley NA; Peake PW; Endre ZH
    Biomark Med; 2013 Jun; 7(3):441-56. PubMed ID: 23734808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.